A Novel Antihepatitis Drug, Bicyclol, Prevents Liver Carcinogenesis in Diethylnitrosamine-Initiated and Phenobarbital-Promoted Mice Tumor Model

Figure 5

Expression and quantification of α-fetal protein (AFP). (a) AFP-immunoreactivity assay in the control and experimental groups at week 20 using immunohistochemistry assay. (A) control; (B) DEN/PB model; (C) treatment with bicyclol (100 mg/kg) before DEN injection; (D) treatment with bicyclol (200 mg/kg) before DEN injection. (b) Quantification of serum and tissue AFP levels in the control and experimental groups at week 20 using an enzyme immunoassay kit. Average values with standard deviations are shown. 𝑛=8–10. ^#𝑃<0.05 compared with the control group; *𝑃<0.05, **𝑃<0.01 compared with the DEN/PB model group. (c) Quantification of liver AFP levels in pregnant mice and fetal mice using an enzyme immunoassay kit. Average values with standard deviations are shown. 𝑛=4. ^#𝑃<0.05 compared with the control group.

(a)

(b)

(c)